ArticleVaccine: X2022

Antibody persistence following administration of a hexavalent DTwP-IPV-HB-PRP∼T vaccine versus separate DTwP-HB-PRP∼T and IPV vaccines at 12-24 months of age and safety and immunogenicity of a booster dose of DTwP-IPV-HB-PRP∼T in healthy infants in India.

S Mangarule et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.